Bayer ha lanzado su nuevo sitio web de transparencia (https://cropscience-transparency.bayer.com), diseñado para permitir el acceso a los datos científicos necesarios para la evaluación de productos fitosanitarios. Con este paso, Bayer está asumiendo un papel de liderazgo en el impulso de la transparencia, al tiempo que protege la composición confidencial de productos y los datos del proceso de fabricación de la empresa.
Además de los resúmenes de los informes de estudios relacionados con la seguridad para un número significativo de sustancias activas, Bayer comenzará a permitir el acceso no comercial a los respectivos informes de estudios relacionados con la seguridad, comenzando con los informes sobre imidacloprid. Se proporciona material de antecedentes, como videos e infografías, para ayudar a poner la ciencia regulatoria en contexto. De esta forma, Bayer quiere fomentar un diálogo abierto y transparente.
“As conflicting accounts about the safety of food or technologies are making it difficult for people to separate fact from fiction, this Bayer initiative is an important step towards increased transparency,” said Dr. Adrian Percy, global head of Research and Development for the Crop Science Division. “By sharing safety data, which was previously only shared with authorities, we hope to connect the public with our scientific community in a way that builds trust and shows our desire to further create transparency.”
“We are excited to launch our new website which also aims to support authorities around the globe by providing an alternative tool, other than filing freedom of information requests, for them to obtain the documents which underlie our registration procedures,” said Percy. “We want non-commercial interested parties – from a concerned citizen to a member of the scientific community – to be able to access safety-relevant information in a way that is quick and easy to understand, so that they can base their opinions on scientific data.”
Bayer’s new transparency website will be updated on a regular basis. In the next phase, which is planned for early 2018, non-commercial users will be able to request access to additional full, in-depth safety-related study reports. Furthermore, Bayer plans to add other language options to its new website, for example German.